Dexmedetomidine Provides Cardioprotection During Early or Late Reperfusion Mediated by Different Mitochondrial K+-Channels.
Journal
Anesthesia and analgesia
ISSN: 1526-7598
Titre abrégé: Anesth Analg
Pays: United States
ID NLM: 1310650
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
pubmed:
6
9
2020
medline:
20
1
2021
entrez:
5
9
2020
Statut:
ppublish
Résumé
Cardioprotective interventions-such as pharmacological postconditioning-are a promising strategy to reduce deleterious consequences of ischemia and reperfusion injury (I/RI) in the heart, especially as timing and onset of myocardial infarction are unpredictable. Pharmacological postconditioning by treatment with dexmedetomidine (Dex), an α2-adrenoreceptor agonist, during reperfusion protects hearts from I/RI, independently of time point and duration of application during the reperfusion phase. The mitochondrial ATP-sensitive K (mKATP) and mitochondrial large-conductance calcium-sensitive potassium channel (mBKCa) play a pivotal role in mediating this cardioprotective effect. Therefore, we investigated whether Dex-induced cardioprotection during early or late reperfusion is mediated variously by these mitochondrial K-channels. Hearts of male Wistar rats were randomized into 8 groups and underwent a protocol of 15 minutes adaption, 33 minutes ischemia, and 60 minutes reperfusion in an in vitro Langendorff-system. A 10-minute treatment phase was started directly (first subgroup, early reperfusion) or 30 minutes (second subgroup, late reperfusion) after the onset of reperfusion. Control (Con) hearts received vehicle only. In the first subgroup, hearts were treated with 3 nM Dex, 100 µM mKATP-channel blocker 5-hydroxydecanoate (5HD) or 1 µM mBKCa-channel blocker Paxilline (Pax) alone or with respective combinations (5HD + Dex, Pax + Dex). Hearts of the second subgroup received Dex alone (Dex30') or in combination with the respective blockers (5HD + Dex30', Pax + Dex30'). Infarct size was determined with triphenyltetrazoliumchloride staining. Hemodynamic variables were recorded during the whole experiment. During early reperfusion (first subgroup), the infarct size reducing effect of Dex (Con: 57% ± 9%, Dex: 31% ± 7%; P< .0001 versus Con) was completely abolished by 5HD and Pax (52% ± 6%; Pax + Dex: 53% ± 4%; each P< .0001 versus Dex), while both blockers alone had no effect on infarct size (5HD: 54% ± 8%, Pax: 53% ± 11%). During late reperfusion (second subgroup) the protective effect of Dex (Dex30': 33% ± 10%, P< .0001 versus Con) was fully abrogated by Pax (Pax + Dex30': 58% ± 7%, P < .0001 versus Dex30'), whereas 5HD did not block cardioprotection (5HD + Dex30': 36% ± 7%). Between groups and within each group throughout reperfusion no significant differences in hemodynamic variables were detected. Cardioprotection by treatment with Dex during early reperfusion seems to be mediated by both mitochondrial K-channels, whereas during late reperfusion only mBKCa-channels are involved.
Sections du résumé
BACKGROUND
Cardioprotective interventions-such as pharmacological postconditioning-are a promising strategy to reduce deleterious consequences of ischemia and reperfusion injury (I/RI) in the heart, especially as timing and onset of myocardial infarction are unpredictable. Pharmacological postconditioning by treatment with dexmedetomidine (Dex), an α2-adrenoreceptor agonist, during reperfusion protects hearts from I/RI, independently of time point and duration of application during the reperfusion phase. The mitochondrial ATP-sensitive K (mKATP) and mitochondrial large-conductance calcium-sensitive potassium channel (mBKCa) play a pivotal role in mediating this cardioprotective effect. Therefore, we investigated whether Dex-induced cardioprotection during early or late reperfusion is mediated variously by these mitochondrial K-channels.
METHODS
Hearts of male Wistar rats were randomized into 8 groups and underwent a protocol of 15 minutes adaption, 33 minutes ischemia, and 60 minutes reperfusion in an in vitro Langendorff-system. A 10-minute treatment phase was started directly (first subgroup, early reperfusion) or 30 minutes (second subgroup, late reperfusion) after the onset of reperfusion. Control (Con) hearts received vehicle only. In the first subgroup, hearts were treated with 3 nM Dex, 100 µM mKATP-channel blocker 5-hydroxydecanoate (5HD) or 1 µM mBKCa-channel blocker Paxilline (Pax) alone or with respective combinations (5HD + Dex, Pax + Dex). Hearts of the second subgroup received Dex alone (Dex30') or in combination with the respective blockers (5HD + Dex30', Pax + Dex30'). Infarct size was determined with triphenyltetrazoliumchloride staining. Hemodynamic variables were recorded during the whole experiment.
RESULTS
During early reperfusion (first subgroup), the infarct size reducing effect of Dex (Con: 57% ± 9%, Dex: 31% ± 7%; P< .0001 versus Con) was completely abolished by 5HD and Pax (52% ± 6%; Pax + Dex: 53% ± 4%; each P< .0001 versus Dex), while both blockers alone had no effect on infarct size (5HD: 54% ± 8%, Pax: 53% ± 11%). During late reperfusion (second subgroup) the protective effect of Dex (Dex30': 33% ± 10%, P< .0001 versus Con) was fully abrogated by Pax (Pax + Dex30': 58% ± 7%, P < .0001 versus Dex30'), whereas 5HD did not block cardioprotection (5HD + Dex30': 36% ± 7%). Between groups and within each group throughout reperfusion no significant differences in hemodynamic variables were detected.
CONCLUSIONS
Cardioprotection by treatment with Dex during early reperfusion seems to be mediated by both mitochondrial K-channels, whereas during late reperfusion only mBKCa-channels are involved.
Identifiants
pubmed: 32889843
doi: 10.1213/ANE.0000000000005148
pii: 00000539-202101000-00034
doi:
Substances chimiques
Adrenergic alpha-2 Receptor Agonists
0
Cardiotonic Agents
0
Potassium Channels
0
Dexmedetomidine
67VB76HONO
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
253-260Références
Caricati-Neto A, Errante PR, Menezes-Rodrigues FS. Recent advances in pharmacological and non-pharmacological strategies of cardioprotection. Int J Mol Sci. 2019;20:4002.
Keating GM. Dexmedetomidine: a review of its use for sedation in the intensive care setting. Drugs. 2015;75:1119–1130.
Bunte S, Behmenburg F, Majewski N, et al. Characteristics of dexmedetomidine postconditioning in the field of myocardial ischemia-reperfusion injury. Anesth Analg. 2020;130:90–98.
Yoshikawa Y, Hirata N, Kawaguchi R, Tokinaga Y, Yamakage M. Dexmedetomidine maintains its direct cardioprotective effect against ischemia/reperfusion injury in hypertensive hypertrophied myocardium. Anesth Analg. 2018;126:443–452.
Behmenburg F, Pickert E, Mathes A, et al. The cardioprotective effect of dexmedetomidine in rats is dose-dependent and mediated by bkca channels. J Cardiovasc Pharmacol. 2017;69:228–235.
Boengler K, Lochnit G, Schulz R. Mitochondria “THE” target of myocardial conditioning. Am J Physiol Heart Circ Physiol. 2018;315:H1215–H1231.
Testai L, Rapposelli S, Martelli A, Breschi MC, Calderone V. Mitochondrial potassium channels as pharmacological target for cardioprotective drugs. Med Res Rev. 2015;35:520–553.
Grover GJ, D’Alonzo AJ, Parham CS, Darbenzio RB. Cardioprotection with the KATP opener cromakalim is not correlated with ischemic myocardial action potential duration. J Cardiovasc Pharmacol. 1995;26:145–152.
Yao Z, Gross GJ. Effects of the KATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Circulation. 1994;89:1769–1775.
Stroethoff M, Christoph I, Behmenburg F, et al. Melatonin receptor agonist ramelteon reduces ischemia-reperfusion injury through activation of mitochondrial potassium channels. J Cardiovasc Pharmacol. 2018;72:106–111.
Obal D, Dettwiler S, Favoccia C, Scharbatke H, Preckel B, Schlack W. The influence of mitochondrial KATP-channels in the cardioprotection of preconditioning and postconditioning by sevoflurane in the rat in vivo. Anesth Analg. 2005;101:1252–1260.
Xu W, Liu Y, Wang S, et al. Cytoprotective role of Ca2 + - activated K + channels in the cardiac inner mitochondrial membrane. Science. 2002;298:1029–1033.
Soltysinska E, Bentzen BH, Barthmes M, et al. KCNMA1 encoded cardiac BK channels afford protection against ischemia-reperfusion injury. PLoS One. 2014;9:e103402.
Sausbier M, Hu H, Arntz C, et al. Cerebellar ataxia and purkinje cell dysfunction caused by Ca2 + -activated K + channel deficiency. Proc Natl Acad Sci USA. 2004;101:9474–9478.
Bentzen BH, Olesen SP, Rønn LC, Grunnet M. BK channel activators and their therapeutic perspectives. Front Physiol. 2014;5:389.
Yuan F, Fu H, Sun K, Wu S, Dong T. Effect of dexmedetomidine on cerebral ischemia-reperfusion rats by activating mitochondrial ATP-sensitive potassium channel. Metab Brain Dis. 2017;32:539–546.
Barsukevich V, Basalay M, Sanchez J, et al. Distinct cardioprotective mechanisms of immediate, early and delayed ischaemic postconditioning. Basic Res Cardiol. 2015;110:452.
Raupach A, Reinle J, Stroethoff M, et al. Milrinone-induced pharmacological preconditioning in cardioprotection: hints for a role of mitochondrial mechanisms. J Clin Med. 2019;8:507.
Behmenburg F, Dorsch M, Huhn R, et al. Impact of mitochondrial Ca2+-sensitive potassium (mBKCa) channels in sildenafil-induced cardioprotection in rats. PLoS One. 2015;10:e0144737.
Yu M, Liu SL, Sun PB, Pan H, Tian CL, Zhang LH. Peptide toxins and small-molecule blockers of BK channels. Acta Pharmacol Sin. 2016;37:56–66.
Zhou Y, Lingle CJ. Paxilline inhibits BK channels by an almost exclusively closed-channel block mechanism. J Gen Physiol. 2014;144:415–440.
Bilmen JG, Wootton LL, Michelangeli F. The mechanism of inhibition of the sarco/endoplasmic reticulum Ca2+ ATPase by paxilline. Arch Biochem Biophys. 2002;406:55–64.
Longland CL, Dyer JL, Michelangeli F. The mycotoxin paxilline inhibits the cerebellar inositol 1,4, 5-trisphosphate receptor. Eur J Pharmacol. 2000;408:219–225.
Zhang JY, Cheng K, Lai D, et al. Cardiac sodium/calcium exchanger preconditioning promotes anti-arrhythmic and cardioprotective effects through mitochondrial calcium-activated potassium channel. Int J Clin Exp Pathol. 2015;8:10239–10249.
Wojtovich AP, Sherman TA, Nadtochiy SM, Urciuoli WR, Brookes PS, Nehrke K. SLO-2 is cytoprotective and contributes to mitochondrial potassium transport. PLoS One. 2011;6:e28287.
Bunte S, Behmenburg F, Bongartz A, et al. Preconditioning by levosimendan is mediated by activation of mitochondrial Ca2+-sensitive potassium (mBKCa) channels. Cardiovasc Drugs Ther. 2018;32:427–434.
Behmenburg F, Trefz L, Dorsch M, et al. Milrinone-induced postconditioning requires activation of mitochondrial Ca2+-sensitive potassium (mBKCa) channels. J Cardiothorac Vasc Anesth. 2018;32:2142–2148.
Goswami SK, Ponnalagu D, Hussain AT, et al. Expression and activation of BKCa channels in mice protects against ischemia-reperfusion injury of isolated hearts by modulating mitochondrial function. Front Cardiovasc Med. 2018;5:194.
Heinen A, Ströthoff M, Schmidt A, et al. Pharmacological options to protect the aged heart from ischemia and reperfusion injury by targeting the PKA-BK(Ca) signaling pathway. Exp Gerontol. 2014;56:99–105.
Shim YH. Cardioprotection and ageing. Korean J Anesthesiol. 2010;58:223–230.
Notsu T, Tanaka I, Takano M, Noma A. Blockade of the ATP-sensitive K + channel by 5-hydroxydecanoate in guinea pig ventricular myocytes. J Pharmacol Exp Ther. 1992;260:702–708.
Paggio A, Checchetto V, Campo A, et al. Identification of an ATP-sensitive potassium channel in mitochondria. Nature. 2019;572:609–613.
Cao S, Liu Y, Wang H, et al. Ischemic postconditioning influences electron transport chain protein turnover in Langendorff-perfused rat hearts. PeerJ. 2016;4:e1706.
Li W, Wu N, Shu W, Jia D, Jia P. Pharmacological preconditioning and postconditioning with nicorandil attenuates ischemia/reperfusion-induced myocardial necrosis and apoptosis in hypercholesterolemic rats. Exp Ther Med. 2015;10:2197–2205.
Lucchinetti E, Jamnicki M, Fischer G, Zaugg M. Preconditioning by isoflurane retains its protection against ischemia-reperfusion injury in postinfarct remodeled rat hearts. Anesth Analg. 2008;106:17–23.
Minaei A, Haghdoost-Yazdi H. Dexmedetomidine attenuates the induction and reverses the progress of 6-hydroxydopamine- induced parkinsonism; involvement of KATP channels, alpha 2 adrenoceptors and anti-inflammatory mechanisms. Toxicol Appl Pharmacol. 2019;382:114743.
Aggarwal S, Randhawa PK, Singh N, Jaggi AS. Role of ATP-sensitive potassium channels in remote ischemic preconditioning induced tissue protection. J Cardiovasc Pharmacol Ther. 2017;22:467–475.
Krolikowski JG, Bienengraeber M, Weihrauch D, Warltier DC, Kersten JR, Pagel PS. Inhibition of mitochondrial permeability transition enhances isoflurane-induced cardioprotection during early reperfusion: the role of mitochondrial KATP channels. Anesth Analg. 2005;101:1590–1596.
Sato T, Saito T, Saegusa N, Nakaya H. Mitochondrial Ca2 + -activated K + channels in cardiac myocytes: a mechanism of the cardioprotective effect and modulation by protein kinase A. Circulation. 2005;111:198–203.
Lindsey ML, Bolli R, Canty JM Jr, et al. Guidelines for experimental models of myocardial ischemia and infarction. Am J Physiol Heart Circ Physiol. 2018;314:H812–H838.